U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H15ClN4O2
Molecular Weight 390.822
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BTA-9881

SMILES

ClC1=CC=C(C=C1)[C@@]23N(CCN2C(=O)C4=C3C=NC=C4)C(=O)C5=CN=CC=C5

InChI

InChIKey=QZSZPSDRJPPZDZ-OAQYLSRUSA-N
InChI=1S/C21H15ClN4O2/c22-16-5-3-15(4-6-16)21-18-13-24-9-7-17(18)20(28)26(21)11-10-25(21)19(27)14-2-1-8-23-12-14/h1-9,12-13H,10-11H2/t21-/m1/s1

HIDE SMILES / InChI

Approval Year

Name Type Language
BTA-9881
Common Name English
MEDI-564
Code English
BTA9881
Code English
AZD-9639
Code English
MEDI 564 [WHO-DD]
Common Name English
5H-IMIDAZO(1',2':1,2)PYRROLO(3,4-C)PYRIDIN-5-ONE, 9B-(4-CHLOROPHENYL)-1,2,3,9B-TETRAHYDRO-1-(3-PYRIDINYLCARBONYL)-, (9BS)-
Systematic Name English
Code System Code Type Description
FDA UNII
9VR1J6U4XG
Created by admin on Sat Dec 16 12:10:21 UTC 2023 , Edited by admin on Sat Dec 16 12:10:21 UTC 2023
PRIMARY
ChEMBL
CHEMBL2109567
Created by admin on Sat Dec 16 12:10:21 UTC 2023 , Edited by admin on Sat Dec 16 12:10:21 UTC 2023
PRIMARY
DRUG BANK
BTA-9881
Created by admin on Sat Dec 16 12:10:21 UTC 2023 , Edited by admin on Sat Dec 16 12:10:21 UTC 2023
PRIMARY BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.BTA9881 is a small molecule fusion glycoprotein inhibitor, designed to specifically inhibit the process by which respiratory syncytial virus (RSV) infects a cell.BTA9881 will be used to stop replication of RSV in an infected patient with the aim of clearing the infection or reducing the clinical impact of the disease. Respiratory syncytial virus (RSV) infects people of all ages, but particularly infants, causing similar symptoms to influenza. In the northern hemisphere, the RSV season usually starts in the fall and runs through the spring. The virus is highly contagious, infecting virtually all infants under the age of two and re-infection is common. For example approximately 50 percent of children will experience two RSV infections by the age of two.
CAS
1646857-24-0
Created by admin on Sat Dec 16 12:10:21 UTC 2023 , Edited by admin on Sat Dec 16 12:10:21 UTC 2023
PRIMARY
PUBCHEM
70807574
Created by admin on Sat Dec 16 12:10:21 UTC 2023 , Edited by admin on Sat Dec 16 12:10:21 UTC 2023
PRIMARY